newsfilter
← Latest News
GlobeNewswire·

TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a